Etrasimod - Pfizer
Alternative Names: APD-334; Etrasimod arginine - Pfizer; PF-07915503; VELSIPITYLatest Information Update: 26 Jul 2024
At a glance
- Originator Arena Pharmaceuticals
- Developer Arena Pharmaceuticals; Everest Medicines; Pfizer
- Class 3-ring heterocyclic compounds; Acetic acids; Amino acids; Anti-inflammatories; Benzene derivatives; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Indoles; Skin disorder therapies; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ulcerative colitis
- Phase II/III Atopic dermatitis; Crohn's disease
- Phase II Eosinophilic oesophagitis
- Discontinued Alopecia areata; Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma gangrenosum
Most Recent Events
- 30 May 2024 Pfizer terminates phase II/III clinical trials in Atopic dermatitis (Treatment-resistant) in USA, Canada, Czech Republic, Poland (PO), due to efficacy reasons only and is not due to any safety concerns (NCT05732454)
- 22 May 2024 Registered for Ulcerative colitis (Treatment-resistant) in Australia (PO)
- 24 Apr 2024 Pfizer granted a Notice of Compliance (NOC) from Health Canada for VELSIPITY™ in Ulcerative Colitis (UC) in Canada